Loading
Advanced Therapy Medicinal Products (atmps) / Gene Therapy / Cell and Gene Therapy Regulation · Journal article
Regenerative Therapy · August 24, 2026
A consensus or society position rather than new primary data.
This narrative review documents the current state of ATMP regulation and development in Saudi Arabia, including eight approved therapies and expanding clinical trial activity in oncology and rare genetic diseases. It surveys regulatory infrastructure, manufacturing capacity, and institutional capabilities rather than evaluating clinical efficacy or outcomes, and serves primarily to characterize the regional landscape for policy and research planning.
Narrative review. Saudi Arabian regulatory authority, healthcare system, clinical trial landscape, and research institutions; no patient population studied.. Saudi Arabia.
Eight ATMPs approved by the SFDA as of 2025, including CAR-T therapies, AAV-based vectors, and CRISPR-based therapies Clinical trial activity concentrated in oncology, hematology, and rare genetic diseases Key institutions (KFSHRC and KAIMARC) have pioneered CAR-T manufacturing capabilities
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review is intended for regulators, institutional leaders, and researchers planning ATMP strategy in Saudi Arabia and similar emerging markets. It does not directly inform individual clinical decisions but documents the infrastructure and policy environment available for advanced therapy implementation.
A narrative review synthesizing regulatory frameworks, guidelines, and implementation status of ATMPs in an emerging market; informs policy and institutional strategy rather than clinical practice or mechanistic evidence.
As stated by the source record.
Quoted from the source exactly as published.
This review is intended for regulators, institutional leaders, and researchers planning ATMP strategy in Saudi Arabia and similar emerging markets. It does not directly inform individual clinical decisions but documents the infrastructure and policy environment available for advanced therapy implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Advanced therapeutic medicinal products (ATMPs) such as gene, somatic cell, and tissue-engineered therapies have transformed modern healthcare by treating previously unmanageable genetic, oncologic, and degenerative diseases. Although regulatory and developmental frameworks for ATMPs are established in the United States, Europe, and China, limited data exist on their implementation in emerging markets such as Saudi Arabia. This review provides the first comprehensive analysis of ATMP regulation and development in Saudi Arabia while offering novel insights into the nation's evolving clinical trial landscape, regulatory infrastructure, and biomanufacturing capabilities. We conducted a narrative review of the Saudi Food and Drug Authority (SFDA) guidelines, peer-reviewed literature, and clinical trial registrations from 2010 to 2025. As of 2025, the SFDA has approved eight ATMPs, including chimeric antigen receptor T-cell therapy (CAR-T) therapies, adeno-associated virus (AAV) based vectors, and clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, reflecting growing regulatory maturity and international alignment. Clinical trial activity continues to expand, with a concentration in oncology, hematology, and rare genetic diseases. National research institutions such as the King Faisal Specialist Hospital and Research Centre (KFSHRC) and King Abdullah International Medical Research Center (KAIMARC) have pioneered advances in CAR-T manufacturing, while biobanking initiatives are driving translational research. Despite ongoing challenges in workforce capacity, good manufacturing practice (GMP) infrastructure, and reimbursement mechanisms, Saudi Arabia is positioned to become a regional leader in advanced therapies through continued regulatory innovation, local manufacturing, and international collaboration.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.